NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

VivoSim Labs, Inc. (VIVS) Stock Analysis

VivoSim Labs, Inc. (VIVS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

VIVS

$0.28

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VIVS with… →

VIVS Key Statistics

As of Sep 4, 2026
Trading
Open
$0.28
Previous Close
$0.28
52-Week Range
0.26–5.30
Volume
267.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.45
Valuation
Market Cap
$3.73M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
33.26
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.54
Financials (FY)
Revenue (FY)
$131.00K−9.03%
Net Income (FY)
−$13.84M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
13.39M
1-Year Return
−87.61%
Dividend and dates
Avg Volume
5.73M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

VIVS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−84.53%
2025−67.21%
2024−58.56%
2023−21.28%
2022−61.16%
2021−70.49%
2020+70.83%
2019−62.50%
2018−28.36%
2017−60.47%
2016 (partial year)−29.52%

As of September 4, 2026.

VIVS Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$131.00K−$13.84M−10567.2%
2024$144.00K−$2.49M−1727.8%
2023$109.00K−$14.67M−13459.6%
2022$370.00K−$17.26M−4664.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$131.00K$131.00K−$11.49M−$13.84M−10567.2%
2024$144.00K$139.00K−$12.62M−$2.49M−1727.8%
2023$109.00K$109.00K−$15.09M−$14.67M−13459.6%
2022$370.00K—−$17.73M−$17.26M−4664.6%

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

VIVS Valuation vs Biotechnology Median

Median of 656 stocks
MetricVIVSBiotechnology medianvs median
P/S ratio33.2615.26118% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

VivoSim Labs, Inc. (VIVS) is capitalised at $3.73M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 15.

The most recent close on file for VIVS is $0.28, dated September 4, 2026. The close was unchanged from the previous session. The 52-week range on file runs from $0.26 to $5.30. The latest close sits 7.69% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $131.00K. Against the prior fiscal year total of $144.00K, that is a change of −9.03%. The same year closed with a net loss of $13.84M. The reported profit margin is 0%. Trailing earnings per share are −4.54.

Across the 4 fiscal years on file, revenue moves from $370.00K in 2022 to $131.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 33.26. On price-to-sales that is 117.92% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is −87.61%. Across 10 years the annualized return works out at −55.54%. The reported beta is 1.45. Annualized volatility over the trailing 10 years is 128.47%.

Growth & Income

No dividend is on file for VIVS.

Across the complete calendar years on file, 2020 returned +70.83% and 2021 returned −70.49%. Of the 9 complete calendar years on file, 1 finished higher. So far in 2026 the price is −84.53%.

Peer Comparison

VivoSim Labs, Inc. (VIVS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
VivoSim Labs, Inc. VIVS $3.73M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. VivoSim Labs, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About VivoSim Labs, Inc.

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and build functional 3D human tissues through its proprietary technologies that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Visit website →